Pharmac does a job almost nobody envies. Working to a fixed budget, it decides which medicines the country funds and which it does not. The system delivers real value, and it necessarily leaves a gap.
For most conditions the gap is theoretical. In oncology it is not. A number of cancer treatments sit outside the funded schedule, and a course can run from tens of thousands of dollars into the hundreds of thousands.
What the money buys
Usually time, and sometimes a good deal of it. Immunotherapies and targeted treatments have changed the outlook for several cancers over the past decade. Some are funded here. Some are funded in Australia and not here. Some are funded here for one indication and not for another.
The distinction that matters clinically, will this help me, and the distinction that matters financially, is this on the schedule, are not the same distinction and they do not move together.
The conversation people end up in
An oncologist explains there is a treatment. It is not funded. There is a family, and there are assets, and the assets are mostly the house.
Households do find the money. They remortgage, they liquidate, they ask relatives, they run public appeals. What they are doing in each case is converting long-term financial security into immediate medical access, at the worst imaginable moment to be negotiating anything.
A narrow, well-defined, low-probability, high-severity risk is precisely the shape insurance handles better than savings do.
Two instruments, different jobs
Trauma cover, sometimes called critical illness cover, pays a lump sum on diagnosis of a defined condition and does not care what you spend it on. That flexibility is the point. It can fund unfunded treatment, replace a spouse's income while they stop work to provide care, or clear the mortgage so that one pressure is removed while you deal with another.
Non-Pharmac drug benefits, attached to a medical policy, reimburse approved unfunded treatments up to a stated limit. Narrower, more specific, generally cheaper per dollar of protection.
They are not alternatives. They answer different questions, and a sensible arrangement usually involves both, sized differently.
Three clauses that decide everything
- The definitions. Trauma policies pay against defined medical events. Early-stage cancers, carcinoma in situ and low-grade prostate cancers are treated very differently between insurers, and the difference does not show up in the premium.
- The limit. A non-Pharmac benefit sounds substantial until it meets a treatment protocol priced well above it. The number has to be read against real treatment costs rather than against how large it feels.
- The approval mechanism. Some policies require the drug to hold Medsafe approval for your specific indication. Some do not. In a field moving this quickly, that clause does a lot of quiet work.
None of this is difficult to establish. It needs someone to read the wording against your circumstances before it matters, rather than after.
Arrange a time to talk. We meet in person, in Hamilton or wherever suits you.
Treatment cost ranges for unfunded cancer therapies as reported in New Zealand trade and consumer press, 2025 and 2026. Individual costs vary considerably by protocol and indication.